Diagnostic Testing & Technology Report

Molecular diagnostics company Gene Express (Wilmington, N.C.) announced on August 11 that it will use the clinical trials service division of NeoGenomics (Ft. Myers, Fla.) to validate its lung cancer risk prediction and BCR/ABL tests, commercialize its tests, and validate future Gene Express technology to meet requirements of the U.S. Food and Drug Administration (FDA). Additionally, a licensing agreement allows NeoGenomics to use Gene Express’s standardized reverse transcription polymerase chain reaction (StaRT-PCR) platform technology for its own commercial activities.